<i>In vitro</i>activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and<i>Acinetobacter baumannii</i>

Abstract

Its superior breadth of activity renders apramycin a promising drug candidate for the treatment of systemic Gram-negative infections that are resistant to treatment with other aminoglycoside antibiotics.